Auteur: Hetero

Lange informatie

Waarvoor wordt dit middel gebruikt?

Lamivudine/Zidovudine Hetero Europe is used to treat HIV (human immunodeficiency virus) infection in adults and children.

Lamivudine/Zidovudine Hetero Europe contains two active ingredients that are used to treat HIV infection: lamivudine and zidovudine. Both of these belong to a group of anti-retroviral medicines called nucleoside analogue reverse transcriptase inhibitors (NRTIs).

Lamivudine/Zidovudine Hetero Europe does not completely cure HIV infection; it reduces the amount of virus in your body, and keeps it at a low level. It also increases the CD4 cell count in your blood. CD4 cells are a type of white blood cells that are important in helping your body to fight infection.

Not everyone responds to treatment with Lamivudine/Zidovudine Hetero Europe in the same way. Your doctor will monitor the effectiveness of your treatment.

Wanneer mag u dit middel niet gebruiken of moet u er extra voorzichtig mee zijn?
Hoe gebruikt u dit middel?
Mogelijke bijwerkingen?
Hoe bewaart u dit middel?
Anvullende Informatie

Wanneer mag u dit middel niet gebruiken of moet u er extra voorzichtig mee zijn?

Do not take Lamivudine/Zidovudine Hetero Europe:

  • if you are allergic to lamivudine or zidovudine or any of the other ingredients of this medicine (listed in section 6).
  • if you have a very low red blood cell count (anaemia) or a very low white blood cell count (neutropenia).

Check with your doctor if you think any of these apply to you.

Warnings and precautions

Some people taking Lamivudine/Zidovudine Hetero Europe or other combination treatments for HIV are more at risk of serious side effects. You need to be aware of the extra risks:

  • if you have ever had liver disease, including hepatitis B or C (if you have hepatitis B infection, don’t stop Lamivudine/Zidovudine Hetero Europewithout your doctor’s advice, as your hepatitis may come back)
  • if you have kidney disease
  • if you are seriously overweight (especially if you are a woman)
  • if you are diabetic and using insulin.

Talk to your doctor if any of these apply to you. Your doctor will decide if the active substances are suitable for you. You may need extra check-ups, including blood tests, while you are taking your medicine. See Section 4 for more information.

Look out for important symptoms

Some people taking medicines for HIV infection develop other conditions, which can be serious. You need to know about important signs and symptoms to look out for while you’re taking Lamivudine/Zidovudine Hetero Europe.

Read the information ‘Other possible side effects of combination therapy for HIV’ in Section 4 of this leaflet.

Protect other people

HIV infection is spread by sexual contact with someone who has the infection, or by transfer of infected blood (for example, by sharing injection needles). Lamivudine/Zidovudine Hetero Europe will not stop you passing HIV infection on to other people. To protect other people from becoming infected with HIV:

  • Use a condom when you have oral or penetrative sex
  • Don’t risk blood transfer – for example, don’t share needles.

Other medicines and Lamivudine/Zidovudine Hetero Europe:

Tell your doctor or pharmacist if you are taking any other medicines, or if you have taken any recently, including herbal medicines or other medicines you bought without a prescription.

Remember to tell you doctor or pharmacist if you begin taking a new medicine while you are taking {(Invented)name}.

These medicines should not be used with Lamivudine/Zidovudine Hetero Europe:

  • other medicinal products containing lamivudine, to treat HIV infection or hepatitis B infection
  • emtricitabine, to treat HIV infection
  • stavudine or zalcitabine, to treat HIV infection
  • ribavirin or injections of ganciclovir to treat viral infections
  • high doses of co-trimoxazole, an antibiotic
  • cladribine, used to treat hairy cell leukaemia.

Tell your doctor if you’re being treated with any of these.

Some medicines can make it more likely that you’ll have side effects, or make side effects worse.

These include:

  • sodium valproate, to treat epilepsy
  • interferon, to treat viral infections
  • pyrimethamine, to treat malaria and other parasitic infections
  • dapsone, to prevent pneumonia and treat skin infections
  • fluconazole or flucytosine, to treat fungal infections such as candida
  • pentamidine or atovaquone to treat parasitic infections such as PCP
  • amphotericin or co-trimoxazole, to treat fungal and bacterial infections
  • probenecid, to treat gout and similar conditions, and given with some antibiotics to make them more effective
  • methadone, used as a heroin substitute
  • vincristine, vinblastine or doxorubicin, to treat cancer.

Tell your doctor if you’re taking any of these.

Some medicines interact with Lamivudine/Zidovudine Hetero Europe

These include:

  • clarithromycin, an antibiotic if you are taking clarithromycin, take your dose at least 2 hours before or after you take your Lamivudine/Zidovudine Hetero Europe.
  • phenytoin, for treating epilepsy.

Tell your doctor if you’re taking phenytoin. Your doctor may need to monitor you while you’re taking Lamivudine/Zidovudine Hetero Europe.

Pregnancy and breast-feeding


If you are pregnant, if you become pregnant or if you are planning to become pregnant talk to your doctor about the risks and benefits to you and your baby of taking Lamivudine/Zidovudine Hetero Europe.

Lamivudine/Zidovudine Hetero Europe and similar medicines may cause side effects in unborn babies. If you become pregnant while you’re taking Lamivudine/Zidovudine Hetero Europe, your baby may be given extra check-ups (including blood tests) to make sure it is developing normally.

Children whose mothers took NRTIs (medicines like Lamivudine/Zidovudine Hetero Europe) during pregnancy had a reduced risk of being infected with HIV. This benefit is greater than the risk of having side effects.


Women who are HIV-positive must not breast-feed, because HIV infection can be passed on to the baby in breast milk.

If you’re breast-feeding or thinking about breast-feeding talk to your doctor immediately.

Driving and using machines

Lamivudine/Zidovudine Hetero Europe can make you dizzy and have other side effects that make you less alert.

Don’t drive or operate machines unless you’re feeling well.

Hoe gebruikt u dit middel?

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Swallow Lamivudine/Zidovudine Hetero Europe film-coated tablets, with some water. Lamivudine/Zidovudine Hetero Europe can be taken with or without food.

If you cannot swallow the tablets whole, you may crush and combine them with a small amount of food or drink, and take all the dose immediately.

Stay in regular contact with your doctor

Lamivudine/Zidovudine Hetero Europe helps to control your condition. You need to keep taking it every day to stop your illness getting worse. You may still develop other infections and illnesses linked to HIV infection.

Keep in touch with your doctor, and do not stop taking Lamivudine/Zidovudine Hetero Europe without your doctor’s advice.

How much to take

Adults and adolescents who weigh 30 kg or more

The usal dose of Lamivudine/Zidovudine Hetero Europe is one tablet twice a day.

Take the tablets at regular times, leaving approximately 12 hours between each tablet.

Children who weigh between 21 and 30 kg

The usual starting dose of Lamivudine/Zidovudine Hetero Europe is one half tablet (½) taken in the morning and one whole tablet taken in the evening.

Children who weigh between 14 and 21 kg

The usual starting dose of Lamivudine/Zidovudine Hetero Europe is one half tablet (½) taken in the morning and one half tablet (½) taken in the evening.

For children who weigh less than 14 kg lamivudine and zidovudine (the ingredients of Lamivudine/Zidovudine Hetero Europe) should be taken separately.

The tablet can be divided into equal doses.

If you take more Lamivudine/Zidovudine Hetero Europe than you should

If you accidentally take too much Lamivudine/Zidovudine Hetero Europe, tell your doctor or your pharmacist, or contact your nearest hospital emergency department for further advice.

If you forget to take Lamivudine/Zidovudine Hetero Europe

If you forget to take a dose, take it as soon as you remember. Then continue your treatment as before. Do not take a double dose to make up for a forgotten dose.

Mogelijke bijwerkingen?

Like all medicines, this medicine can cause side effects, although not everybody gets them.

When you’re being treated for HIV, it can be hard to tell whether a symptom is a side effect of Lamivudine/Zidovudine Hetero Europe, or other medicines you’re taking, or an effect of the HIV disease itself. So it is very important to talk to your doctor about any changes in your health.

As well as the side effects listed below for Lamivudine/Zidovudine Hetero Europe, other conditions can develop during combination therapy for HIV. It is important to read the information later in this section under ‘Other possible side effects of combination therapy for HIV’.

Very common side effects

These may affect more than 1 in 10 people:

  • headache
  • feeling sick (nausea)

Common side effects

These may affect up to 1 in 10 people:

  • being sick (vomiting)
  • diarrhoea
  • stomach pains
  • loss of appetite
  • feeling dizzy
  • tiredness, lack of energy
  • fever (high temperature)
  • general feeling of being unwell
  • difficulty in sleeping (insomnia)
  • muscle pain and discomfort
  • joint pain
  • cough
  • irritated or runny nose
  • skin rash
  • hair loss (alopecia).

Common side effects that might show up in blood tests are:

  • a low red blood cell count (anaemia) or low white blood cell count (neutropenia or leucopenia)
  • an increase in the level of liver enzymes
  • an increased amount in the blood of bilirubin (a substance produced in the liver) which may make your skin appear yellow.

Uncommon side effects

These may affect up to 1 in 100 people:

  • feeling breathless
  • wind (flatulence)
  • itching
  • muscle weakness

An uncommon side effect that may show up in blood test is:

  • a decrease in the number of cells involved in blood clotting (thrombocytopenia) or in all kinds of blood cells (pancytopenia).

Rare side effects

These may affect up to 1 in 1000 people:

  • serious allergic reaction causing swelling of the face, tongue or throat which may cause difficulty in swallowing or breathing
  • liver disorders, such as jaundice, enlarged liver or fatty liver, inflammation (hepatitis)
  • lactic acidosis (see the next section, ‘Other possible side effects of combination therapy for HIV’)
  • inflammation of the pancreas (pancreatitis)
  • chest pain; disease of the heart muscle (cardiomyopathy)
  • fits (convulsions)
  • feeling depressed or anxious, not being able to concentrate, feeling drowsy
  • indigestion, taste disturbance
  • changes in the colour of your nails, your skin or the skin inside your mouth
  • a flu-like feeling – chills and sweating
  • tingly feelings in the skin (pins and needles)
  • sensation of weakness in the limbs
  • breakdown of muscle tissue

  • numbness
  • passing urine more often
  • enlarged breasts in men

Rare side effects that may show up in blood tests are:

  • an increase in an enzyme called amylase
  • a failure of the bone marrow to produce new red blood cells (pure red cell aplasia).

Very rare side effects

These may affect up to 1 in 10,000 people:

A very rare side effect that may show up in blood tests is:

  • a failure of the bone marrow to produce new red or white blood cells (aplastic anaemia).

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects

not listed in this leaflet. You can also report side effects directly via the national reporting system listed in

Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

Other possible side effects of combination therapy for HIV

Combination therapy such as Lamivudine/Zidovudine Hetero Europe may cause other conditions to develop during HIV treatment.

Old infections may flare up

People with advanced HIV infection (AIDS) have weak immune systems, and are more likely to develop serious infections (opportunistic infections). When these people start treatment, they may find that old, hidden infections flare up, causing signs and symptoms of inflammation. These symptoms are probably caused by the body’s immune system becoming stronger, so that the body starts to fight these infections.

In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after the start of treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.

If you get any symptoms of infection while you’re taking Lamivudine/Zidovudine Hetero Europe:

Tell your doctor immediately. Do not take other medicines for the infection without your doctor’s advice.

Your body shape may change

People taking combination therapy for HIV may find that their body shape changes, because of changes in fat distribution:

  • fat may be lost from the legs, arms or face
  • extra fat may build up around the tummy (abdomen), or on the breasts or internal organs
  • fatty lumps (sometimes called buffalo hump) may appear on the back of the neck.

It is not yet known what causes these changes, or whether they have any long-term effects on your health. If you notice changes in your body shape tell your doctor.

Lactic acidosis is a rare but serious side effect

Some people taking Lamivudine/Zidovudine Hetero Europe, or other medicines like it (NRTIs), develop a condition called lactic acidosis, together with an enlarged liver.

Lactic acidosis is caused by a build up of lactic acid in the body. It is rare; if it happens, it usually develops after a few months of treatment. It can be life-threatening, causing failure of internal organs. Lactic acidosis is more likely to develop in people who have liver disease, or in obese (very overweight) people, especially women.

Signs of lactic acidosis include:

  • deep, rapid, difficult breathing
  • drowsiness
  • numbness or weakness in the limbs
  • feeling sick (nausea), being sick (vomiting)
  • stomach pain.

During your treatment, your doctor will monitor you for signs of lactic acidosis. If you have any of the symptoms listed above or any other symptoms that worry you see your doctor as soon as possible.

You may have problems with your bones

Some people taking combination therapy for HIV develop a condition called osteonecrosis. With this condition, parts of the bone tissue die because of reduced blood supply to the bone. People may be more likely to get this condition:

  • if they have been taking combination therapy for a long time
  • if they are also taking anti-inflammatory medicines called corticosteroids
  • if they drink alcohol
  • if their immune systems are very weak
  • if they are overweight.

Signs of osteonecrosis include:

  • stiffness in the joints
  • aches and pains (especially in the hip, knee or shoulder)
  • difficulty moving.

If you notice any of these symptoms tell your doctor.

Other effects may show up in blood tests

Combination therapy for HIV can also cause:

  • increased levels of lactic acid in the blood, which on rare occasions can lead to lactic acidosis
  • increased levels of sugar and fats (triglycerides and cholesterol) in the blood
  • resistance to insulin (so if you’re diabetic, you may have to change your insulin dose to control your blood sugar).

Hoe bewaart u dit middel?

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month. Do not use this medicine after three months of first opening the HDPE container.

This medicinal product does not require any special storage conditions

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Anvullende Informatie

What Lamivudine/Zidovudine Hetero Europe contains

  • The active substances are lamivudine and zidovudine. Each film-coated tablet contains 150 mg of lamivudine and 300 mg of zidovudine.
  • The other ingredients are
    • tablet core: cellulose microcrystalline, sodium starch glycolate, magnesium stearate
    • tablet film-coat: titanium dioxide, hypromellose, macrogol/PEG 400, polysorbate 80

What Lamivudine/Zidovudine Hetero Europe looks like and contents of the pack

Lamivudine/Zidovudine Hetero Europe film-coated tablets are supplied in blisters in cartons containing 60, 120 or 200 film-coated tablets and in bottle packs containing 60 and 500 film-coated tablets.

Lamivudine/Zidovudine Hetero Europe are white to off-white, capsule shaped, biconvex, scored film-coated tablets, debossed with ‘I’ on one side and ‘115’ on other side.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder

Hetero Europe S.L.

Viladecans Business Park – Edificio Brasil

Catalunya 83-85

08840 Viladecans (Barcelona)



Pharmadox Healthcare Ltd.

KW 20A Kordin lndustrial Park

Paola PLA 3000


In het Register ingeschreven onder:

RVG 112406

This medicinal product is authorised in the Member States of the EEA under the following names:

Portugal: Lamivudina/Zidovudina Hetero Europe 150 mg/300 mg comprimido revestido por película

Ijsland: Lamivudine/Zidovudine LYFIS 150 mg/300 mg filmuhúðaðar töflur Duitsland: Lamivudin/Zidovudin Hetero Europe 150 mg/300 mg Filmtabletten Nederland: Lamivudine/Zidovudine Hetero Europe 150 mg/300 mg, filmomhulde tabletten

Deze bijsluiter is voor het laatst goedgekeurd in augustus 2013

Cookies help us deliver our services. By using our services, you agree to our use of cookies. OK